346 related articles for article (PubMed ID: 8508427)
21. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial.
Waters JS; Norman A; Cunningham D; Scarffe JH; Webb A; Harper P; Joffe JK; Mackean M; Mansi J; Leahy M; Hill A; Oates J; Rao S; Nicolson M; Hickish T
Br J Cancer; 1999 Apr; 80(1-2):269-72. PubMed ID: 10390007
[TBL] [Abstract][Full Text] [Related]
22. High-dose, brief duration, multiagent chemotherapy for metastatic breast cancer.
Lamar RE; Greco FA; Johnson DH; Murphy PB; Hainsworth JD
Cancer; 1994 Apr; 73(7):1842-8. PubMed ID: 8137208
[TBL] [Abstract][Full Text] [Related]
23. Chemotherapy for operable gastric cancer: results of the Dutch randomised FAMTX trial. The Dutch Gastric Cancer Group (DGCG).
Songun I; Keizer HJ; Hermans J; Klementschitsch P; de Vries JE; Wils JA; van der Bijl J; van Krieken JH; van de Velde CJ
Eur J Cancer; 1999 Apr; 35(4):558-62. PubMed ID: 10492627
[TBL] [Abstract][Full Text] [Related]
24. Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407).
Nishina T; Boku N; Gotoh M; Shimada Y; Hamamoto Y; Yasui H; Yamaguchi K; Kawai H; Nakayama N; Amagai K; Mizusawa J; Nakamura K; Shirao K; Ohtsu A;
Gastric Cancer; 2016 Jul; 19(3):902-10. PubMed ID: 26386560
[TBL] [Abstract][Full Text] [Related]
25. Sequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with peritoneal dissemination: a retrospective study.
Tahara M; Ohtsu A; Boku N; Nagashima F; Muto M; Sano Y; Yoshida M; Mera K; Hironaka S; Tajiri H; Yoshida S
Gastric Cancer; 2001; 4(4):212-8. PubMed ID: 11846065
[TBL] [Abstract][Full Text] [Related]
26. A phase II study of sequential methotrexate and 5-fluorouracil chemotherapy in previously treated gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group, JCOG 9207 trial.
Hamaguchi T; Shirao K; Yamamichi N; Hyodo I; Koizumi W; Seki S; Imamura T; Honma H; Ohtsu A; Boku N; Mukai T; Yamamoto S; Fukuda H; Yoshida S;
Jpn J Clin Oncol; 2008 Jun; 38(6):432-7. PubMed ID: 18515821
[TBL] [Abstract][Full Text] [Related]
27. A phase II trial of sequential MTx and 5-FU alternated with 4-epidoxorubicin and cisplatin in advanced gastric cancer.
Taal BG; ten Bokkel Huinink WW; Simonetti G; Franklin H; McVie JG
Cancer Invest; 1990; 8(5):501-4. PubMed ID: 2265372
[TBL] [Abstract][Full Text] [Related]
28. The combination of cisplatin, doxorubicin, and mitomycin (PAM) compared with the FAM regimen in treating advanced gastric carcinoma. A phase II randomized trial of the Italian Oncology Group for Clinical Research.
De Lisi V; Cocconi G; Angelini F; Cavicchi F; Di Costanzo F; Gilli G; RodinĂ² C; Soldani M; Tonato M; Finardi C
Cancer; 1996 Jan; 77(2):245-50. PubMed ID: 8625230
[TBL] [Abstract][Full Text] [Related]
29. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
[TBL] [Abstract][Full Text] [Related]
30. A phase I/II study of vinorelbine, doxorubicin, and methotrexate with leucovorin rescue as first-line treatment for metastatic breast cancer.
Subramanyan S; Abeloff MD; Bond SE; Davidson NE; Fetting JH; Gordon GB; Kennedy MJ
Cancer Chemother Pharmacol; 1999; 43(6):497-502. PubMed ID: 10321510
[TBL] [Abstract][Full Text] [Related]
31. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
[TBL] [Abstract][Full Text] [Related]
32. Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study.
Felici A; Carlini P; Ruggeri EM; Gamucci T; Pollera CF; De Marco S; Fariello AM; Moscetti L; Gelibter A; Adami E; Sperduti I; Cognetti F
Cancer Chemother Pharmacol; 2006 Jan; 57(1):59-64. PubMed ID: 16001173
[TBL] [Abstract][Full Text] [Related]
33. 5-Fluorouracil, methotrexate, leucovorin, CDDP and epirubicin (FEPMTX): a wide-spectrum regimen of salvage chemotherapy for high-grade advanced gastric cancer.
Kinoshita K; Yonemura Y; Sawa T; Miyata T; Sakuma H; Matsuki N; Tanaka S; Fushida S; Fujimura T; Mok YJ; Kim BS; Lee JI; Choi DW; Song YJ; Yang DH; Kwon SJ; Tanaka M; Miyazaki I
Hepatogastroenterology; 2003; 50(53):1716-9. PubMed ID: 14571825
[TBL] [Abstract][Full Text] [Related]
34. Long-term results with FAMTX (5-fluorouracil, adriamycin, methotrexate) in advanced gastric cancer.
Klein HO
Anticancer Res; 1989; 9(4):1025-6. PubMed ID: 2817784
[TBL] [Abstract][Full Text] [Related]
35. Biochemical modulation of 5-fluorouracil with methotrexate in advanced colorectal cancer patients pretreated with adjuvant 5-fluorouracil and leucovorin.
Pronzato P; Vaira F; Vigani A; Losardo P; Bertelli G
Anticancer Res; 1995; 15(6B):2679-82. PubMed ID: 8669846
[TBL] [Abstract][Full Text] [Related]
36. Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial.
Hartgrink HH; van de Velde CJ; Putter H; Songun I; Tesselaar ME; Kranenbarg EK; de Vries JE; Wils JA; van der Bijl J; van Krieken JH;
Eur J Surg Oncol; 2004 Aug; 30(6):643-9. PubMed ID: 15256239
[TBL] [Abstract][Full Text] [Related]
37. Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL)--a very effective regimen with good patients' compliance for advanced gastric cancer.
Cheng AL; Yeh KH; Lin JT; Hsu C; Liu MY
Anticancer Res; 1998; 18(2B):1267-72. PubMed ID: 9615799
[TBL] [Abstract][Full Text] [Related]
38. New developments in the treatment of gastric carcinoma.
Wilke H; Preusser P; Fink U; Achterrath W; Meyer HJ; Stahl M; Lenaz L; Meyer J; Siewert JR; Geerlings H
Semin Oncol; 1990 Feb; 17(1 Suppl 2):61-70. PubMed ID: 2305269
[TBL] [Abstract][Full Text] [Related]
39. A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer.
Kollmannsberger C; Quietzsch D; Haag C; Lingenfelser T; Schroeder M; Hartmann JT; Baronius W; Hempel V; Clemens M; Kanz L; Bokemeyer C
Br J Cancer; 2000 Aug; 83(4):458-62. PubMed ID: 10945491
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of 5-fluorouracil, pirarubicin and low-dose consecutive administration of cisplatin for advanced and recurrent gastric cancer.
Kikuyama S; Inada T; Miyakita M; Ogata Y
Jpn J Clin Oncol; 1998 May; 28(5):314-7. PubMed ID: 9703858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]